Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Hess

Showing results (71-80 of 94) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumorsLajos Pusztai, Mark Ayers, James Stec, et al.
JAMA Network Open|March 20, 2020
Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate CancerAlexander F Bagley, Mitchell S Anscher, Seungtaek Choi, et al.
Journal for Immunotherapy of Cancer|October 14, 2020
Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trialJames Welsh, Hari Menon, Dawei Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2007
Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant gliomaJohn G Kuhn, Susan M Chang, Patrick Y Wen, et al.
Oncoscience|January 15, 2015
Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experienceFernando F Corrales-Medina, Cynthia Herzog, Kenneth Hess, et al.
Clinical Breast Cancer|July 29, 2014
Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unitDebora de Melo Gagliato, Denis L Fontes Jardim, Gerald Falchook, et al.
Oncotarget|November 7, 2014
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumabGerald S Falchook, Jennifer J Wheler, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinicChad Tang, Kenneth Hess, Denis Leonardo F Jardim, et al.
Annals of Surgery|August 23, 2002
Treatment outcomes of resected esophageal cancerWayne Hofstetter, Stephen G Swisher, Arlene M Correa, et al.
Oncology|November 2, 2016
Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient UnitHolly Kinahan, Abhishek Maiti, Kenneth Hess, et al.
Pageof 10

Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumorsLajos Pusztai, Mark Ayers, James Stec, et al.
JAMA Network Open|March 20, 2020
Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate CancerAlexander F Bagley, Mitchell S Anscher, Seungtaek Choi, et al.
Journal for Immunotherapy of Cancer|October 14, 2020
Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trialJames Welsh, Hari Menon, Dawei Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2007
Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant gliomaJohn G Kuhn, Susan M Chang, Patrick Y Wen, et al.
Oncoscience|January 15, 2015
Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experienceFernando F Corrales-Medina, Cynthia Herzog, Kenneth Hess, et al.
Clinical Breast Cancer|July 29, 2014
Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unitDebora de Melo Gagliato, Denis L Fontes Jardim, Gerald Falchook, et al.
Oncotarget|November 7, 2014
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumabGerald S Falchook, Jennifer J Wheler, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinicChad Tang, Kenneth Hess, Denis Leonardo F Jardim, et al.
Annals of Surgery|August 23, 2002
Treatment outcomes of resected esophageal cancerWayne Hofstetter, Stephen G Swisher, Arlene M Correa, et al.
Oncology|November 2, 2016
Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient UnitHolly Kinahan, Abhishek Maiti, Kenneth Hess, et al.
Pageof 10